Venetoclax Combined With Azactidine in the Treatment of ALAL

The prognosis of acute leukaemias of ambiguous lineage is poor. The effect of chemotherapy regimen and hematopoietic stem cell transplantation are still unclear. Therefore, we will explore new therapy to improve the remission rate of acute leukaemias of ambiguous lineage. Venetoclax can significantly improve the remission rate and prolong PFS and OS. At present, venetoclax combined with azacitidine or decitabine has become the preferred treatment regimen for elderly AML patients. It also shows a high response rate in relapsed/refractory AML or MDS patients. There are few clinical studies on th

Trial Details

NCT ID
NCT05901974
Phase
PHASE2
Sponsor
Sheng-Li Xue, MD
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Venetoclax
  • azactidine
Locations (sample)
  • Suzhou, China|31.30408,120.59538

Key Eligibility Criteria

  • Patients aged ≥ 15 years.
  • Patients diagnosed with ALAL according to 5th edition of WHO Acute Leukaemias of Ambiguous Lineage diagnosis standard.
  • New diagnosed patients.
  • ECOG performance status score less than 3.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →